Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 86 |
| Active Pipeline (Recruiting Now) | 38 (23) |
| Completed vs Stopped Early | 31 / 17 (19.8%) |
| Median Closed Actual Enrollment | 31 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| NYU Langone Health and Perlmutter Cancer Center | New York, NY | 81 |
| Columbia University Irving Medical Center | New York, NY | 5 |
| Huntsman Cancer Institute at University of Utah | Salt Lake City, UT | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05799378 | Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | Phase III | RECRUITING |
| NCT04474223 | Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) | Phase III | ACTIVE NOT RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for NYU Langone Health across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the NYU Langone Health Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.